5-ALA ( DrugBank: 5-ALA )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 180 | ＡＴＲ−Ｘ症候群 | 1 |
180. ＡＴＲ−Ｘ症候群
臨床試験数 : 1 / 薬物数 : 3 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2051220062 | 14/07/2022 | 14/07/2022 | Physician-initiated clinical trial in patients with 5-aminolevulinic acid-induced ATR-X syndrome. | Exploratory study to investigate the safety and efficacy of NPJ005 in patients with ATR-X syndrome. - IACT21003 | ATR-X syndrome infant, intellectual disability, epigenetics, guanine quadruplex;D008607 | Containing 5-aminolevulinic acid (5-ALA) hydrochloride and sodium ferrous citrate (SFC) Tablets (25 mg 5-ALA hydrochloride/39.2 mg SFC per tablet, NPJ005) for 24 weeks | Wada Takahito | NULL | Recruiting | >= 2age old | Not applicable | Male | 5 | Phase 2 | Japan |